TLR-independent small molecule adjuvants
US-9918959-B2 · Mar 20, 2018 · US
Diprovocims: a new and potent class of TLR agonists
US11040959B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11040959-B2 |
| Application number | US-201716303043-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2017 |
| Priority date | Jun 29, 2016 |
| Publication date | Jun 22, 2021 |
| Grant date | Jun 22, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R 1 , R 2 , R 3 and R 4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. The immunostimulatory activity of a diprovocim compound is similar to that of LPS, to which there is no apparent structural similarity. A contemplated compound bears no structural similarity to either the TLR1/TLR2 lipoprotein agonists nor to any other synthetic TLR agonist, and is remarkably easy to prepare and synthetically modify.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula V, wherein -A is —H (hydrido) or —C(O)NH-R 4 ; R 1 , R 2 , R 3 and R 4 are the same or different and are a 2-(4-fluorophenyl)ethyl, a trans-2-phenylcyclopropyl, a trans-2-(4-fluorophenyl)-cyclopropyl or a C 3 -C 18 hydrocarbyl group with the provisos that: 1) at least two of R 1 , R 2 , R 3 and R 4 (R 1-4 ) or a…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- C07D207/16Primary
Chemistry & Metallurgy · mapped topic
- C07D403/10Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11040959B2 cover?
- A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R 1 , R 2 , R 3 and R 4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. The immunost…
- Who is the assignee on this patent?
- Scripps Research Inst, Univ Texas, Beutler Bruce, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D207/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).